---
title: 'Australian experience with ibrutinib in patients with relapsed/refractory
  mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry'
date: '2024-02-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38376128/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240220170715&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Bruton's tyrosine kinase inhibitors (BTKi) have an established role in
  the management of patients with relapsed/refractory mantle cell lymphoma (MCL).
  However, scant data exist on outcomes of patients ineligible for clinical trials
  testing these therapies. We describe a contemporary cohort of relapsed/refractory
  MCL patients from the Australasian Lymphoma and Related Diseases Registry treated
  with ibrutinib December 2014 until July 2018, to determine the proportion potentially
  eligible ...
disable_comments: true
---
Bruton's tyrosine kinase inhibitors (BTKi) have an established role in the management of patients with relapsed/refractory mantle cell lymphoma (MCL). However, scant data exist on outcomes of patients ineligible for clinical trials testing these therapies. We describe a contemporary cohort of relapsed/refractory MCL patients from the Australasian Lymphoma and Related Diseases Registry treated with ibrutinib December 2014 until July 2018, to determine the proportion potentially eligible ...